Find all our press releases by year, by clicking on the button below.
Find all the financial documents relating to our investors classified in three main categories, by clicking below.
Find all the investor presentations listed by year, by clicking below.
| Firm | Analyst |
| Genesta Finance/Aurgalys | Jean-Pierre Loza – jp.loza@aurgalys.com |
| Edison | Maxim Jacobs – mjacobs@edisongroup.com |
| Invest Securities | Olga Smolentseva – osmolentseva@invest-securities.com |
| Kepler Cheuvreux Equity Research | Thomas Landemaine, Ph.D. – tlandemaine@keplercheuvreux.com |
| Gilbert Dupont | Jamila El Bougrini |
Quantum Genomics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Quantum Genomics’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Quantum Genomics or its management. Quantum Genomics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
To access the analysis, click on the link Research public access and fill in its status to create an account LINK
Welcome to the page dedicated to our shareholder Letters. We hope to make this communication tool a way of providing you with in-depth information on a regular basis to help you understand our strategy and how our projects are progressing.
The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 27, 2019, at 10 am, in the offices of AARPI, located 36 Avenue Hoche, 75008 Paris.
The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 14, 2018, at 10 am, in the offices of AARPI, located 36 Avenue Hoche, 75008 Paris.
The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 8, 2017, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.
All the resolutions were approved during the general meeting.
Holders of redeemable share subscription warrants issued on June 8, 2017 (BSAR 2017) are called to attend the Annual General Meeting on June 15, 2016 at 9:50 am in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.
The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 15, 2016, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.
Holders of redeemable share subscription warrants issued on March 14, 2016 (BSAR 2016) are called to attend the Annual General Meeting on June 15, 2016 at 9:50 am in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.
The general meeting of shareholders of Quantum Genomics company will be held Tuesday, December 22, 2015, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.
The general meeting of shareholders of Quantum Genomics company will be held Tuesday, June 30, 2015, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.
The general meeting of shareholders of Quantum Genomics company will be held Monday, June 30, 2014, at 4 pm, in the offices of SCP Lerner Friggeri & Associés (Cabinet Orsay), located 146/150 Champs Elysees – 75008 Paris.
Share capital of Quantum Genomics
Date: February 29, 2020
Total number of shares
Total number of voting rights
No new share was issued during February 2020.
Main stock information
| ISIN Code | FR0011648971 |
| Mnemonic | ALQGC |
| Listing market | Alternext – Euronext Paris |
| PEA (Share savings plans) and PEA-PME | Yes |
| SRD (Deferred settlement) | No |
Quantum Genomics is a limited company with a board of directors. The compositions of the Board and Executive Committee of the Company are set out in the Company tab.
All publications will happen after the close of the Euronext markets.
March, 26th 2020
2019 Annual Results
June, 25th 2020
General Meeting of Shareholders
October, 1st 2020
2020 Half-Year Results
For questions of financial order, please contact Benoit Gueugnon by completing the form.